A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)

I3Y-MC-JPBJ -

The main purpose of this study is to evaluate the safety and tolerability of abemaciclib in combination with another anti-cancer drug in participants with NSCLC that is advanced or has spread to other parts of the body (stage IV). The study will also investigate how the body processes the combination treatment and how the study drug affects the body. The study will also collect disease-related symptoms and participant-reported pain related to NSCLC.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Lung Cancer
What the trial is testing?
Ramucirumab, Abemaciclib, Pemetrexed, Gemcitabine, Trametinib
Could I receive a Placebo?
No
Enrollment Goal
142
Trial Dates
Mar 28, 2014 - Aug 29, 2019
How long will I be in the trial?
Depending on how you and your tumor respond to treatment, your study participation could last until your disease worsens or until you and your doctor decide to stop treatment.
Trial Phase
I

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.